Benlysta® (belimumab) Intravenous Injection

Covers IV belimumab for FDA‑approved active SLE and active lupus nephritis in patients ≥5 years, and excludes use in patients <5 years, SLE without autoantibody positivity, or lupus nephritis without biopsy confirmation. Key requirements: concurrent use with at least one standard therapy (or documented intolerance) — for lupus nephritis an immunosuppressive regimen — prescribing by or in consultation with an appropriate specialist, documented clinical response for reauthorization, and approvals limited to 12 months.

"Patients aged 5 years and older with active systemic lupus erythematosus (SLE) who are receiving standard therapy."

Sign up to see full coverage criteria, indications, and limitations.